Exchange Traded Concepts LLC Reduces Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Exchange Traded Concepts LLC decreased its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 15.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 70,082 shares of the company’s stock after selling 12,931 shares during the period. Exchange Traded Concepts LLC owned 0.12% of Health Catalyst worth $570,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HCAT. Principal Financial Group Inc. lifted its holdings in Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after buying an additional 1,907 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Health Catalyst by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after purchasing an additional 2,164 shares in the last quarter. Quarry LP increased its position in shares of Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Health Catalyst by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after acquiring an additional 2,831 shares during the period. Finally, ClariVest Asset Management LLC increased its position in shares of Health Catalyst by 1.2% in the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after acquiring an additional 3,302 shares during the period. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Up 0.1 %

NASDAQ HCAT opened at $8.66 on Friday. The stock has a market capitalization of $511.24 million, a P/E ratio of -4.68 and a beta of 1.32. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41. The firm has a 50-day moving average price of $7.71 and a 200 day moving average price of $6.94.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.21) earnings per share. On average, equities research analysts expect that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the transaction, the chief operating officer now owns 134,899 shares of the company’s stock, valued at $1,036,024.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the transaction, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at $1,036,024.32. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,396 shares of company stock valued at $258,415 over the last quarter. Company insiders own 2.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Stephens lowered their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Evercore ISI raised their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Piper Sandler cut their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus price target of $11.58.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.